Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 9, 2026Diabetes TherapyOpen Access

Dulaglutide reduced MACE by 12% compared to placebo over 5.4 years

View Full Paper
Ask AI
Bookmark
Share

Key result

Dulaglutide reduced MACE by 12% compared to placebo over 5.4 years

Authors

JMJosé Pablo Miramontes-GonzálezÁRÁlvaro Rodrigo-AlaízMGMiriam Gabella-Martín

Discussion

Loading...

Member takes

Overview

This research demonstrates the potential of incretin-based therapies to improve cardiovascular and renal outcomes in patients with T2DM, suggesting a shift in treatment focus.

Key Points

  • The aim is to explore how incretin modulation can enhance cardiovascular and renal health in diabetes therapy.
  • Analysis of incretin-based therapy impact on cardiovascular and renal outcomes.
  • Review of guidelines supporting GLP-1RA usage in high-risk patients.
  • Consideration of dual agonists and small-molecule agents within clinical contexts.
  • GLP-1RA show effectiveness in reducing cardiovascular and renal risks regardless of glucose control.
  • Potential for expanded treatment options with dual agonists and novel oral agents pending further evidence.

PICO

P
Population
type 2 diabetes mellitus with chronic kidney disease and/or cardiovascular disease (n=9,901)
I
Intervention / Comparator
dulaglutide vs placebo (1.5 mg weekly)
O
Primary Outcome
major adverse cardiovascular events (MACE) — HR 0.88 (0.79–0.99)

Main Result

Effect estimate: HR 0.88 (95% CI 0.79–0.99)

Limitations

  • The study population included mainly low-risk individuals compared to T2DM patients with established cardiovascular events.

Cite This Study

Miramontes-González et al. (2026) studied type 2 diabetes mellitus with chronic kidney disease and/or cardiovascular disease (n=9,901). dulaglutide vs. placebo was evaluated on major adverse cardiovascular events (MACE) (HR 0.88, 95% CI 0.79–0.99). Dulaglutide reduced MACE by 12% compared to placebo over 5.4 years.

synapsesocial.com/papers/69612fd330ef6c21f6853ceahttps://doi.org/10.1007/s13300-025-01829-1
View Full Paper
Ask AI
Bookmark
Share